SC
IPXL

Sophrosyne Capital’s Impax Laboratories, Inc. IPXL Stock Holding History

Sophrosyne Capital’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-90,400
Closed -$1.8M – 74
2013
Q2 		$1.8M Buy
+90,400
New +$1.6M 1.41% 22

Other funds holding IPXL

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sophrosyne Capital's IPXL Position: Q3 2013 in Review

Sophrosyne Capital sold out of Impax Laboratories, Inc. (IPXL) in Q3 2013, closing a stake of 90,400 shares — an estimated $1.8M sold.

Sophrosyne Capital first reported a position in IPXL in Q2 2013 and held it in 1 quarter. The position peaked at $1.8M in Q2 2013. 158 funds tracked by Wall St. Rank hold IPXL as of Q3 2013.

  • Sophrosyne Capital reported no remaining Impax Laboratories, Inc. position as of Q3 2013 after selling out during the quarter.
  • Sophrosyne Capital sold 90,400 Impax Laboratories, Inc. shares in Q3 2013, an estimated $1.8M.
  • Sophrosyne Capital first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 1 quarter.
  • Sophrosyne Capital's Impax Laboratories, Inc. position peaked at $1.8M in Q2 2013.
  • 158 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2013.

Based on Sophrosyne Capital's 13F filing for Q3 2013, filed 14 Nov 2013.